Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Operating Leases (2019 - 2025)

Anika Therapeutics (ANIK) has disclosed Operating Leases for 7 consecutive years, with $26.2 million as the latest value for Q4 2025.

  • Quarterly Operating Leases rose 9.3% to $26.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.2 million through Dec 2025, up 9.3% year-over-year, with the annual reading at $26.2 million for FY2025, 9.3% up from the prior year.
  • Operating Leases for Q4 2025 was $26.2 million at Anika Therapeutics, up from $22.8 million in the prior quarter.
  • The five-year high for Operating Leases was $29.7 million in Q2 2022, with the low at $18.8 million in Q1 2022.
  • Average Operating Leases over 5 years is $24.6 million, with a median of $25.5 million recorded in 2024.
  • The sharpest move saw Operating Leases soared 50.27% in 2023, then fell 10.56% in 2025.
  • Over 5 years, Operating Leases stood at $19.2 million in 2021, then surged by 49.78% to $28.8 million in 2022, then decreased by 10.07% to $25.9 million in 2023, then decreased by 7.34% to $24.0 million in 2024, then grew by 9.3% to $26.2 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $26.2 million, $22.8 million, and $23.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.